Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Alanine aminotransferase, Alpha 1 globulin, Alpha 2 globulin, Anion gap, Aspartate aminotransferase
Clinical narrative: Beta%, Serum (Electrophoresis-serum protein): 8.3 (standard range:9-17% ); Total  Protein - SEP: 8.6 (Standard range: 6.0-8.0 g/dL); Gamma%: 8.7 (Standard range: 9-21% ); Creatinine: 1.07 (Standard range: 0.4-1.00 mg/dL); eGFR Non African American: 53 (Standard range: >60 mL/min); Total protein: 8.6 (Standard range: 6.0-8.0 g/dL); Absolute Lymph Count: 0.98 (Standard range: 1.0-4.8 K/UL); Lymphocytes: 19 (Standard range: 24-44%); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in deltoid left, administration date 11Feb2021 07:30 (Lot number: EL9264, Batch number: 01003592671000231721053110) at the age of 56 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Psoriatic Arthritis", start date: Jun2012 (ongoing), notes: Currently in severe flare during time that coincided with Pfizer shots.; "Arthritis pain" (unspecified if ongoing), notes: on as needed meloxicam; "High Risk Smoldering Multiple Myeloma", start date: Mar2015 (ongoing); "Depression" (ongoing), notes: on Sertraline; "Anxiety" (ongoing), notes: on Trazodone; "Migraine" (ongoing), notes: on Eletriptan and topimarate (for migraine prevention). Concomitant medication(s) included: SERTRALINE taken for depression, start date: 2008 (ongoing); TRAZODONE taken for anxiety, start date: 2008 (ongoing); TOPIRAMATE taken for migraine prophylaxis, start date: 2008 (ongoing); MELOXICAM taken for arthritis, start date: 2008; ELETRIPTAN taken for migraine, start date: 2020 (ongoing). Past drug history included: Sumatriptan, start date: 2008, stop date: 2020, for Migraine, notes: Route: oral. Vaccination history included: Bnt162b2 (dose 1, single, Anatomical site of injection: Left Shoulder, Route of administration: Intramuscular, Lot number: EL9261, Batch: 359267100023), administration date: 22Jan2021, when the patient was 56 years old, for COVID-19 Immunisation, reaction(s): "aggravated arthritis pain/psoriatic arthritis, currently in severe aggravated "Flare" during time that coincided with Pfizer shots", "started menses after having been post menopausal for one year menses was light lasted one week", "tiredness". The following information was reported: ELECTROPHORESIS PROTEIN ABNORMAL (non-serious) with onset 23Feb2021, outcome "unknown", described as "Beta%, Serum (Electrophoresis-serum protein): 8.3 (standard range:9-17% ); Total  Protein - SEP: 8.6 (Standard range: 6.0-8.0 g/dL); Gamma%: 8.7 (Standard range: 9-21% )"; BLOOD CREATININE INCREASED (non-serious) with onset 23Feb2021, outcome "unknown", described as "Creatinine: 1.07 (Standard range: 0.4-1.00 mg/dL)"; GLOMERULAR FILTRATION RATE DECREASED (non-serious) with onset 23Feb2021, outcome "unknown", described as 53 (Standard range: >60 mL/min)"; PROTEIN TOTAL INCREASED (non-serious) with onset 23Feb2021, outcome "unknown", described as "Total protein: 8.6 (Standard range: 6.0-8.0 g/dL)"; LYMPHOCYTE COUNT DECREASED (non-serious) with onset 23Feb2021, outcome "unknown", described as "Absolute Lymph Count: 0.98 (Standard range: 1.0-4.8 K/UL); Lymphocytes: 19 (Standard range: 24-44%)". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient has no prior vaccinations. It was also reported that there was no any other side effects occurred after the second vaccine.   No follow-up attempts are possible. No further information is expected.